Xiamen Boson Biotech Co., Ltd.

Rapid SARS-CoV-2 Antigen Test Card

April 6, 2022

Coronavirus
Disease 2019
(COVID-19)

This Fact Sheet informs you of the significant known and potential risks and benefits of the emergency use of the Rapid SARS-CoV-2 Antigen Test Card.

The Rapid SARS-CoV-2 Antigen Test Card is a single use rapid lateral flow chromatographic immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2. This test is authorized for non-prescription home use with self-collected anterior nasal (nares) swab samples from individuals aged 14 and older, when tested twice over three days with at least 24 hours (and no more than 48 hours) between tests. The test is authorized for individuals with symptoms of COVID-19 within the first 6 days of symptom onset, or individuals without symptoms or other epidemiological reasons to suspect COVID-19.

This test is also authorized for non-prescription home use with adult-collected anterior nasal (nares) swab samples from individuals aged 2 years and older when tested twice over three days with at least 24 hours (and no more than 48 hours) between tests. The test is authorized for individuals aged 2 years and older with symptoms of COVID-19 within the first 6 days of symptom onset, or individuals without symptoms or other epidemiological reasons to suspect COVID-19.

All individuals who use this assay are required to receive and should carefully review the Rapid SARS-CoV-2 Antigen Test Card Instructions for Use before they use the test.

What are the symptoms of COVID-19?

Many individuals with confirmed COVID-19 have developed fever and/or symptoms of acute respiratory illness (e.g., cough, dyspnea), although some individuals experience only mild symptoms or no symptoms at all. The current information available to characterize the spectrum of clinical illness associated with COVID-19 suggests that, when present, symptoms include cough, shortness of breath or dyspnea, fever, chills, myalgias, headache, sore throat, new loss of taste or smell, nausea or vomiting or diarrhea. Signs and symptoms may appear any time from 2 to 14 days after exposure to the virus, and the median time to symptom onset is

approximately 5 days. For further information on the symptoms of COVID-19 please see the link provided in "Where can I go for updates and more information?" section.

This test for use at home with self-collected anterior nasal (nares) swab samples from individuals aged two years or older as described below.

Public health officials have identified cases of COVID-19 throughout the world, including the United States. Please check the CDC COVID-19 webpage (see link provided in "Where can I go for updates and more information?" section at the end of this document) or your local jurisdictions website for the most up to date information.

What do I need to know about COVID-19 testing? Current information on COVID-19 for healthcare providers is available at CDC's webpage, *Information for Healthcare Professionals* (see links provided in "Where can I go for updates and more information?" section).

- This test is authorized for non-prescription home use with self-collected anterior nasal swab samples from individuals aged 14 years and older, when tested twice over three days with at least 24 hours (and no more than 48 hours) between tests. The test is authorized for individuals with symptoms of COVID-19 within the first 6 days of symptom onset, or without symptoms or other epidemiological reasons to suspect COVID-19.
- This test is also authorized for non-prescription home use with adult-collected anterior nasal (nares) swab samples from individuals aged 2 years and older when tested twice over three days with at least 24 hours (and no more than 48 hours) between tests. The test is authorized for individuals 2 years and older with symptoms of COVID-19 within the first 6 days of symptom onset, or without symptoms or other epidemiological reasons to suspect COVID-19.

Report Adverse events, including problems with test performance or results, to MedWatch by submitting the online FDA Form 3500 (https://www.accessdata.fda.gov/scripts/medwatch/index.cfm?action=reporting.home) or by calling **1-800-FDA-1088**

Xiamen Boson Biotech Co., Ltd.

Rapid SARS-CoV-2 Antigen Test Card

April 6, 2022

Coronavirus
Disease 2019
(COVID-19)

What does it mean if the specimen tests positive for the virus that causes COVID-19?

A positive test result for COVID-19 indicates that antigens from SARS-CoV-2 were detected, and therefore the patient is infected with the virus and presumed to be contagious. COVID-19 test results should always be considered in the context of clinical observations and epidemiological data (such as local prevalence rates and current outbreak/epicenter locations) in making a final diagnosis and patient management decisions. Patient management should be made by a healthcare provider and follow current CDC guidelines.

The Rapid SARS-CoV-2 Antigen Test Card has been designed to minimize the likelihood of false positive test results. However, in the event of a false positive result, risks to patients could include the following: a recommendation for isolation of the patient, monitoring of household or other close contacts for symptoms, patient isolation that might limit contact with family or friends and may increase contact with other potential COVID-19 patients, limits in the ability to work, delayed diagnosis and treatment for the true infection causing the symptoms, unnecessary prescription of a treatment or therapy, or other unintended adverse effects.

All healthcare providers must follow the standard testing and reporting guidelines according to their appropriate public health authorities.

What does it mean if both specimens test negative for the virus that causes COVID-19?

A negative test result for this test means that SARS-CoV-2 antigens were not present in the specimen above the limit of detection. However, a negative result does not rule out COVID-19 and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Antigen tests are known to be less sensitive than molecular tests that detect viral nucleic acids. The amount of antigen in a sample may decrease as the duration of illness increases. Specimens collected after day 6 of illness may be more likely to be negative compared to a RT-PCR assay. Therefore, negative results should be treated as presumptive and confirmation with a molecular assay, if necessary, for patient management may be performed.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. The possibility of a false negative result should especially be considered if the patient's recent exposures or clinical presentation indicate that COVID-19 is likely, and diagnostic tests for other causes of illness (e.g., other respiratory illness) are negative. If COVID-19 is still suspected based on exposure history together with other clinical findings, re-testing or testing with molecular methods should be considered by healthcare providers in consultation with public health authorities.

Risks to a patient of a false negative test result include: delayed or lack of supportive treatment, lack of monitoring of infected individuals and their household or other close contacts for symptoms resulting in increased risk of spread of COVID-19 within the community, or other unintended adverse events.

A negative antigen test should not be the sole basis used to determine if a patient can end isolation precautions. For additional recommendations regarding infection control, refer to CDC's Discontinuation of Isolation for Persons with COVID-19 Not in Healthcare Settings (Interim Guidance) (see links provided in "Where can I go for updates and more information?" section).

The performance of this test was established based on the evaluation of a limited number of clinical specimens collected between January and February 2022. The clinical performance has not been established in all circulating variants but is anticipated to be reflective of the prevalent variants in circulation at the time and location of the clinical evaluation. Performance at the time of testing may vary depending on the variants circulating, including newly emerging strains of SARS-CoV-2 and their prevalence, which change over time.

What do I need to know about Serial Testing?
Serial testing may assist in identifying infected individuals and facilitate timely infection control practices. A negative test result does not rule out infection but repeat testing over two or three days may decrease the risk of false negative results.

Report Adverse events, including problems with test performance or results, to MedWatch by submitting the online FDA Form 3500 (https://www.accessdata.fda.gov/scripts/medwatch/index.cfm?action=reporting.home) or by calling **1-800-FDA-1088**

Xiamen Boson Biotech Co., Ltd.

Rapid SARS-CoV-2 Antigen Test Card

April 6, 2022

Coronavirus
Disease 2019
(COVID-19)

Additional clinical studies are underway to assess the performance of rapid antigen tests when used with serial testing. An initial negative test result should be the first of a minimum of two tests. An individual undergoing serial testing with two or more negative results may require ongoing serial testing or confirmatory testing, depending on patient history and potential exposures. An individual undergoing serial testing with one or more positive results indicates that SARS-CoV-2 antigen is present, but does not rule out coinfection with other pathogens. Both symptomatic and asymptomatic individuals should undergo serial testing with this test.

Additional confirmatory testing with a molecular test for negative results may be necessary if there is a high likelihood of SARS-CoV-2 infection, such as, an individual with a close contact with COVID-19 or with suspected exposure to COVID-19 or in communities with high prevalence of infection. Additional confirmatory testing with a molecular test for positive results may also be necessary, if there is a low likelihood of SARS-CoV-2 infection, such as in individuals without known exposures to SARS-CoV-2 or residing in communities with low prevalence of infection. For additional recommendations regarding confirmation of antigen test results, please refer to the CDC's Interim Guidance for Antigen Testing for SARS-CoV-2 (see links provided in "Where can I go for updates and more information?" section).

What is an EUA?

The United States FDA has made this test available under an emergency access mechanism called an Emergency Use Authorization (EUA). The EUA is supported by the Secretary of Health and Human Service's (HHS's) declaration that circumstances exist to justify the emergency use of in vitro diagnostics (IVDs) for the detection and/or diagnosis of the virus that causes COVID-19. An IVD made available under an EUA has not undergone the same type of review as an FDA-approved or cleared IVD. FDA may issue an EUA when certain criteria are met, which includes that there are no adequate, approved, available alternatives, and based on the totality of scientific evidence available, it is reasonable to believe that this IVD may be effective in diagnosing COVID-19. The EUA for this test is in effect for the duration of the COVID-19 declaration justifying

emergency use of IVDs, unless terminated or revoked (after which the test may no longer be used).

What are the approved available alternatives?

There are no approved available alternative antigen tests. Any tests that have received full marketing status (e.g., cleared, approved), as opposed to an EUA, by FDA can be found by searching the medical device databases here: https://www.fda.gov/medical-device-databases. A cleared or approved test should be used instead of a test made available under an EUA, when appropriate and available. FDA has issued EUAs for other tests that can be found at:

https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization.

Xiamen Boson Biotech Co., Ltd.

Rapid SARS-CoV-2 Antigen Test Card

April 6, 2022

Coronavirus
Disease 2019
(COVID-19)

Where can I go for updates and more information?

CDC webpages:

General: https://www.cdc.gov/coronavirus/2019-

ncov/index.html
Symptoms:

https://www.cdc.gov/coronavirus/2019-ncov/symptoms-

testing/symptoms.html

Healthcare Professionals:

https://www.cdc.gov/coronavirus/2019-nCoV/hcp/index.html

Information for Laboratories:

https://www.cdc.gov/coronavirus/2019-nCoV/lab/index.html

Laboratory Biosafety:

https://www.cdc.gov/coronavirus/2019-nCoV/lab-biosafety-quidelines.html

Isolation Precautions in Healthcare Settings:

https://www.cdc.gov/infectioncontrol/guidelines/isolation/index.

<u>html</u>

Specimen Collection: https://www.cdc.gov/coronavirus/2019-

nCoV/lab/guidelines-clinical-specimens.html

Infection Control: https://www.cdc.gov/coronavirus/2019-

ncov/php/infection-control.html

FDA webpages:

General: www.fda.gov/novelcoronavirus

EUAs:(includes links to fact sheet for individuals and manufacturer's instructions) https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas

Xiamen Boson Biotech Co., Ltd.

90-94 Tianfeng Road, Jimei North Industrial Park, Xiamen, Fujian, 361021, P.R.China.

Customer Support:

+1-888-352-8394 support@bosoncovt.com

Technical Support:

+1-888-352-8394

support@bosoncovt.com